Controlled Substances: Proposed Revised Aggregate Production Quotas for 2005, 45432-45435 [05-15493]
Download as PDF
<![CDATA[
45432
Federal Register / Vol. 70, No. 150 / Friday, August 5, 2005 / Notices
a. Prohibiting Brokers from offering
consumers any type of rebate or
inducement, including but not limited
to, cash rebates, free products and
services such as televisions or home
inspections, discounts or vouchers for
products and services such as home
moving services or home improvement
stores, and donations to charities on the
customer’s behalf, on the basis that such
conduct violates the Commission’s
administrative regulations;
b. Prohibiting rebates or other
inducements in private contracts that
involve Brokers; and
c. Preventing Brokers from offering
rebates or other inducements by among
other things:
i. Investigating alleged violations of
the Rebate Ban;
ii. Asking Brokers to inform the
Commission when one or more
competing Brokers offers rebates or
other inducements;
iii. Instructing Brokers to cease
offering rebates or other inducements;
iv. Threatening to bring disciplinary
actions against Brokers unless they
cease offering rebates or other
inducements;
v. Bringing disciplinary actions
against Brokers for offering rebates or
other inducements; and
vi. Sanctioning Brokers the
Commission has found to have offered
rebates or other inducements by one or
more of the following: suspending
licenses, revoking licenses, imposing
monetary fines, issuing reprimands, and
requiring completion of additional
academic credit hours.
34. The Rebate Ban also enables
sellers and/or seller Brokers to fix the
commission at which the buyer’s Broker
is to be compensated in a particular real
estate transaction, thereby insulating the
Brokers from competing among
themselves on the basis of price when
they enter into agreements with buyers.
35. As a result of the Rebate Ban,
Brokers cannot—and thus need not—
compete with one another by offering
rebates or other valuable inducements.
36. The Commission has worked
closely with Brokers and Brokers’
associations, including the Association,
in its continued enforcement of the
Rebate Ban. Among other things, the
Commission has rejected proposals to
eliminate the Rebate Ban as recently as
2004 after receiving substantial
opposition from Brokers.
Anticompetitive Effects
37. The Rebate Ban has injured, and
continues to injure, buyers and sellers of
real property throughout Kentucky. The
Rebate Ban restricts competition and
deprives the property-buying and
VerDate jul<14>2003
15:34 Aug 04, 2005
Jkt 205001
property-selling public of a myriad of
price and non-price discounts,
including, but not limited to, cash
rebates, vouchers or coupons, and
discounted or free services related to
buying and selling property such as
home inspections, title services, or
moving services. These rebates and
inducements benefit consumers. Real
estate brokers and sales associates
operating in states without a similar ban
offer rebates, inducements, and many of
the discounts set forth above to buyers
and sellers as they compete to offer their
services to buyers and sellers. Such
rebates, for example, may amount to
several thousand dollars in a single
transaction.
38. The agreements, combinations, or
conspiracies alleged herein have had,
and will continue to have,
anticompetitive effects, including:
a. A suppression of price competition
in the provision of real estate brokerage
services;
b. The limitation of products and
services available to buyers and sellers
of property; and
c. The creation of barriers to entry
into the provision of real estate
brokerage services by companies that
offer rebates, discounts, and reduced
commissions as part of their business
model.
Violation Alleged
39. The allegations of paragraphs 1
through 38 of this Complaint are realleged and incorporated by reference
herein with the same force and effect as
though set forth in full.
40. Defendant’s promulgation,
adoption, maintenance, and
enforcement of regulations 201 Ky.
Admin. Reg. 11:011, Section 1(5) and
201 Ky. Admin. Reg. 11:121, Section
1(2) arise from and result in agreements,
combinations, or conspiracies that
restrain competition in numerous
Kentucky real estate brokerage service
markets in violation of Section 1 of the
Sherman Act, 15 U.S.C. 1.
Request for Relief
Wherefore, the United States prays
that final judgment be entered against
Defendant declaring, ordering, and
adjudicating that:
a. The agreements, combinations, or
conspiracies alleged herein restrain
trade and are illegal under Section 1 of
the Sherman Act, 15 U.S.C. 1;
b. Defendant be restrained and
enjoined from, either directly or
indirectly, prohibiting Brokers from
advertising or offering rebates or
inducements;
c. Defendant’s regulations 201 Ky.
Admin. Reg. 11:011, Section 1(5) and
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
201 Ky. Admin. Reg. 11:121, Section
1(2) are preempted by the federal
antitrust laws and are null and void;
d. Defendant shall mail a copy of the
Complaint, order, and explanatory
notice to:
i. Each Commissioner, director,
representative, agent, and employee of
Defendant Kentucky Real Estate
Commission; and
ii. Each person licensed to provide
real estate brokerage in Kentucky;
e. Defendant publish in its Newsletter
the explanatory notice and an article
stating that the regulations prohibiting
rebates and inducements have been
eliminated;
f. The United States recover its costs
in this action; and
g. Such other relief as the United
States may request and that the Court
deems just and proper.
Dated: March 30, 2005.
Respectfully submitted:
For Plaintiff United States of America.
R. Hewitt Pate,
Assistant Attorney General.
Thomas O. Barnett,
Deputy Assistant Attorney General.
Dorothy B. Fountain,
Deputy Director of Operations.
John R. Read,
Chief, Litigation III.
Nina Hale,
Assistant Chief, Litigation III.
Owen M. Kendler,
Mary Beth McGee,
Mark A. Merva,
Maurice E. Stucke,
Attorneys.
United States Department of Justice,
Antitrust Division, Litigation III; 325 7th
Street, NW., Suite 300, Washington, DC
20530. (202) 616–5935.
[FR Doc. 05–15489 Filed 8–4–05; 8:45 am]
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–259R]
Controlled Substances: Proposed
Revised Aggregate Production Quotas
for 2005
Drug Enforcement
Administration (DEA), Justice.
ACTION: Notice of proposed revised 2005
aggregate production quotas.
AGENCY:
SUMMARY: This notice proposes revised
2005 aggregate production quotas for
controlled substances in Schedules I
and II of the Controlled Substances Act
(CSA).
DATES: Written comments must be
postmarked, and electronic comments
E:\FR\FM\05AUN1.SGM
05AUN1
Federal Register / Vol. 70, No. 150 / Friday, August 5, 2005 / Notices
must be sent, on or before August 26,
2005.
To ensure proper handling
of comments, please reference ‘‘Docket
No. DEA–259R on all written and
electronic correspondence. Written
comments being sent via regular mail
should be sent to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, Washington, DC 20537,
Attention: DEA Federal Register
Representative/ODL. Written comments
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, VA 22301. Comments may
be directly sent to DEA electronically by
sending an electronic message to
dea.diversion.policy@usdoj.gov.
Comments may also be sent
electronically through https://
www.regulations.gov using the
electronic comment form provided on
that site. An electronic copy of this
document is also available at the
https://www.regulations.gov Web site.
DEA will accept attachments to
electronic comments in Microsoft Word,
WordPerfect, Adobe PDF, or Excel file
formats only. DEA will not accept any
ADDRESSES:
file format other than those specifically
listed here.
FOR FURTHER INFORMATION CONTACT:
Christine A. Sannerud, Ph.D., Chief,
Drug and Chemical Evaluation Section,
Drug Enforcement Administration,
Washington, DC 20537, Telephone:
(202) 307–7183.
SUPPLEMENTARY INFORMATION: Section
306 of the CSA (21 U.S.C. 826) requires
that the Attorney General establish
aggregate production quotas for each
basic class of controlled substance listed
in Schedules I and II. This
responsibility has been delegated to the
Administrator of the DEA by Section
0.100 of Title 28 of the Code of Federal
Regulations. The Administrator, in turn,
has redelegated this function to the
Deputy Administrator, pursuant to
Section 0.104 of Title 28 of the Code of
Federal Regulations.
On January 3, 2005, DEA published a
notice of established initial 2005
aggregate production quotas for certain
controlled substances in Schedules I
and II (70 FR 120). This notice
stipulated that the DEA would adjust
the quotas in early 2005 as provided for
in Part 1303 of Title 21 of the Code of
Federal Regulations.
The proposed revised 2005 aggregate
production quotas represent those
quantities of controlled substances in
Schedules I and II that may be produced
in the United States in 2005 to provide
adequate supplies of each substance for:
the estimated medical, scientific,
research and industrial needs of the
United States; lawful export
requirements; and the establishment
and maintenance of reserve stocks.
These quotas do not include imports of
controlled substances for use in
industrial processes.
The proposed revisions are based on
a review of 2004 year-end inventories,
2004 disposition data submitted by
quota applicants, estimates of the
medical needs of the United States,
product development, and other
information available to the DEA.
Therefore, under the authority vested
in the Attorney General by Section 306
of the CSA of 1970 (21 U.S.C. 826),
delegated to the Administrator of the
DEA by Section 0.100 of Title 28 of the
Code of Federal Regulations, and
redelegated to the Deputy Administrator
pursuant to Section 0.104 of Title 28 of
the Code of Federal Regulations, the
Deputy Administrator hereby proposes
the following revised 2005 aggregate
production quotas for the following
controlled substances, expressed in
grams of anhydrous acid or base:
Previously established initial 2005
quotas
(grams)
Basic class—schedule I
2,5-Dimethoxyamphetamine ..........................................................................................................
2,5-Dimethoxy-4-ethylamphetamine (DOET) ................................................................................
2,5-Dimethoxy-4-(n)-propylthiophenethylamine .............................................................................
3-Methylfentanyl .............................................................................................................................
3-Methylthiofentanyl .......................................................................................................................
3,4-Methylenedioxyamphetamine (MDA) ......................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .......................................................................
3,4-Methylenedioxymethamphetamine(MDMA) .............................................................................
3,4,5-Trimethoxyamphetamine ......................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (DOB) ................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (2–CB) ...........................................................................
4-Methoxyamphetamine ................................................................................................................
4-Methylaminorex ..........................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (DOM) ................................................................................
5-Methoxy-3,4-methylenedioxyamphetamine ................................................................................
5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) ....................................................................
Acetyl-alpha-methylfentanyl ...........................................................................................................
Acetyldihydrocodeine .....................................................................................................................
Acetylmethadol ..............................................................................................................................
Allylprodine ....................................................................................................................................
Alphacetylmethadol ........................................................................................................................
Alpha-ethyltryptamine ....................................................................................................................
Alphameprodine .............................................................................................................................
Alphamethadol ...............................................................................................................................
Alpha-methyltryptamine (AMT) ......................................................................................................
Alpha-methylfentanyl .....................................................................................................................
Alpha-methylthiofentanyl ................................................................................................................
Aminorex ........................................................................................................................................
Benzylmorphine .............................................................................................................................
Betacetylmethadol .........................................................................................................................
Beta-hydroxy-3-methylfentanyl ......................................................................................................
Beta-hydroxyfentanyl .....................................................................................................................
Betameprodine ...............................................................................................................................
Betamethadol .................................................................................................................................
VerDate jul<14>2003
15:34 Aug 04, 2005
Jkt 205001
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
45433
E:\FR\FM\05AUN1.SGM
2,801,000
2
10
2
2
15
5
15
2
2
2
2
2
2
2
10
2
2
2
2
2
2
2
3
10
2
2
2
2
2
2
2
2
2
05AUN1
Proposed revised 2005
quotas
(grams)
2,801,000
2
10
2
2
15
5
17
2
2
2
5
2
2
2
10
2
2
2
2
2
2
2
3
10
2
2
2
2
2
2
2
2
2
45434
Federal Register / Vol. 70, No. 150 / Friday, August 5, 2005 / Notices
Previously established initial 2005
quotas
(grams)
Basic class—schedule I
Betaprodine ....................................................................................................................................
Bufotenine ......................................................................................................................................
Cathinone .......................................................................................................................................
Codeine-N-oxide ............................................................................................................................
Diethyltryptamine ...........................................................................................................................
Difenoxin ........................................................................................................................................
Dihydromorphine ............................................................................................................................
Dimethyltryptamine ........................................................................................................................
Gamma-hydroxybutyric acid ..........................................................................................................
Heroin ............................................................................................................................................
Hydromorphinol ..............................................................................................................................
Hydroxypethidine ...........................................................................................................................
Lysergic acid diethylamide (LSD) ..................................................................................................
Marihuana ......................................................................................................................................
Mescaline .......................................................................................................................................
Methaqualone ................................................................................................................................
Methcathinone ...............................................................................................................................
Methyldihydromorphine ..................................................................................................................
Morphine-N-oxide ..........................................................................................................................
N,N-Dimethylamphetamine ............................................................................................................
N-Ethylamphetamine .....................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine ................................................................................
Noracymethadol .............................................................................................................................
Norlevorphanol ...............................................................................................................................
Normethadone ...............................................................................................................................
Normorphine ..................................................................................................................................
Para-fluorofentanyl .........................................................................................................................
Phenomorphan ..............................................................................................................................
Pholcodine .....................................................................................................................................
Propiram ........................................................................................................................................
Psilocybin .......................................................................................................................................
Psilocyn ..........................................................................................................................................
Tetrahydrocannabinols ..................................................................................................................
Thiofentanyl ...................................................................................................................................
Trimeperidine .................................................................................................................................
Proposed revised 2005
quotas
(grams)
2
2
2
252
2
5,000
1,551,000
3
8,000,000
2
2
2
61
913,020
2
5
4
2
252
2
2
2
2
52
2
12
2
2
2
50,000
2
7
312,500
2
2
Previously established initial 2005
quotas
(grams)
Basic class—schedule II
1-Phenylcyclohexylamine ....................................................................................................................
Alfentanil ..............................................................................................................................................
Alphaprodine ........................................................................................................................................
Amobarbital ..........................................................................................................................................
Amphetamine .......................................................................................................................................
Cocaine ................................................................................................................................................
Codeine (for sale) ................................................................................................................................
Codeine (for conversion) .....................................................................................................................
Dextropropoxyphene ............................................................................................................................
Dihydrocodeine ....................................................................................................................................
Diphenoxylate ......................................................................................................................................
Ecgonine ..............................................................................................................................................
Ethylmorphine ......................................................................................................................................
Fentanyl ...............................................................................................................................................
Glutethimide .........................................................................................................................................
Hydrocodone (for sale) ........................................................................................................................
Hydrocodone (for conversion) .............................................................................................................
Hydromorphone ...................................................................................................................................
Isomethadone ......................................................................................................................................
Levo-alphacetylmethadol (LAAM) ........................................................................................................
Levomethorphan ..................................................................................................................................
Levorphanol .........................................................................................................................................
Meperidine ...........................................................................................................................................
Metazocine ...........................................................................................................................................
Methadone (for sale) ...........................................................................................................................
Methadone Intermediate ......................................................................................................................
Methamphetamine ...............................................................................................................................
2
2,500
2
2
12,700,000
228,000
39,605,000
55,000,000
167,365,000
748,000
571,000
53,000
2
1,428,000
2
37,604,000
1,500,000
2,751,000
2
2
2
5,000
9,753,000
1
13,900,000
18,000,000
2,932,000
2
2
2
252
2
5,000
1,826,000
3
8,000,000
2
2
2
61
4,500,000
2
5
4
2
252
2
2
2
2
52
2
12
2
2
2
50,000
2
7
312,500
2
2
Proposed revised
2005 quotas
(grams)
2
2,500
2
2
14,500,000
228,000
39,605,000
55,000,000
167,365,000
750,000
828,000
73,000
2
1,428,000
2
37,604,000
1,500,000
3,300,000
2
2
2
5,000
9,753,000
1
15,490,000
19,208,000
2,340,000
[680,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 1,615,000 grams for methamphetamine mostly for
conversion to a Schedule III product; and 45,000 grams for methamphetamine (for sale)]
Methylphenidate ...................................................................................................................................
VerDate jul<14>2003
17:08 Aug 04, 2005
Jkt 205001
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
E:\FR\FM\05AUN1.SGM
30,817,000
05AUN1
35,000,000 g
45435
Federal Register / Vol. 70, No. 150 / Friday, August 5, 2005 / Notices
Previously established initial 2005
quotas
(grams)
Basic class—schedule II
Morphine (for sale) ..............................................................................................................................
Morphine (for conversion) ....................................................................................................................
Nabilone ...............................................................................................................................................
Noroxymorphone (for sale) ..................................................................................................................
Noroxymorphone (for conversion) .......................................................................................................
Opium ..................................................................................................................................................
Oxycodone (for sale) ...........................................................................................................................
Oxycodone (for conversion) ................................................................................................................
Oxymorphone ......................................................................................................................................
Pentobarbital ........................................................................................................................................
Phencyclidine .......................................................................................................................................
Phenmetrazine .....................................................................................................................................
Racemethorphan .................................................................................................................................
Remifentanil .........................................................................................................................................
Secobarbital .........................................................................................................................................
Sufentanil .............................................................................................................................................
Thebaine ..............................................................................................................................................
The Deputy Administrator further
proposes that aggregate production
quotas for all other Schedules I and II
controlled substances included in
Sections 1308.11 and 1308.12 of Title 21
of the Code of Federal Regulations
remain at zero.
All interested persons are invited to
submit their comments in writing or
electronically regarding this proposal
following the procedures in the
‘‘Addresses’’ section of this document.
A person may object to or comment on
the proposal relating to any of the
above-mentioned substances without
filing comments or objections regarding
the others. If a person believes that one
or more of these issues warrant a
hearing, the individual should so state
and summarize the reasons for this
belief.
In the event that comments or
objections to this proposal raise one or
more issues which the Deputy
Administrator finds warrant a hearing,
the Deputy Administrator shall order a
public hearing by notice in the Federal
Register, summarizing the issues to be
heard and setting the time for the
hearing as per 21 CFR 1303.13(c).
The Office of Management and Budget
has determined that notices of aggregate
production quotas are not subject to
centralized review under Executive
Order 12866.
This action does not preempt or
modify any provision of state law; nor
does it impose enforcement
responsibilities on any state; nor does it
diminish the power of any state to
enforce its own laws. Accordingly, this
action does not have federalism
implications warranting the application
of Executive Order 13132.
The Deputy Administrator hereby
certifies that this action will not have a
VerDate jul<14>2003
17:08 Aug 04, 2005
Jkt 205001
significant impact upon small entities
whose interests must be considered
under the Regulatory Flexibility Act, 5
U.S.C. 601 et seq. The establishment of
aggregate production quotas for
Schedules I and II controlled substances
is mandated by law and by international
treaty obligations. The quotas are
necessary to provide for the estimated
medical, scientific, research and
industrial needs of the United States, for
export requirements and the
establishment and maintenance of
reserve stocks. While aggregate
production quotas are of primary
importance to large manufacturers, their
impact upon small entities is neither
negative nor beneficial. Accordingly, the
Deputy Administrator has determined
that this action does not require a
regulatory flexibility analysis.
This action meets the applicable
standards set forth in Sections 3(a) and
3(b)(2) of Executive Order 12988 Civil
Justice Reform.
This action will not result in the
expenditure by State, local, and tribal
governments, in the aggregate, or by the
private sector, of $115,000,000 or more
in any one year, and will not
significantly or uniquely affect small
governments. Therefore, no actions were
deemed necessary under the provisions
of the Unfunded Mandates Reform Act
of 1995.
This action is not a major rule as
defined by Section 804 of the Small
Business Regulatory Enforcement
Fairness Act of 1996. This action will
not result in an annual effect on the
economy of $100,000,000 or more; a
major increase in costs or prices; or
significant adverse effects on
competition, employment, investment,
productivity, innovation, or on the
ability of United States-based
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
Proposed revised
2005 quotas
(grams)
35,000,000
110,774,000
2
1,002
4,000,000
1,180,000
49,200,000
920,000
534,000
18,251,000
2,006
2
2
0
2
4,000
72,453,000
35,000,000
110,774,000
2
1,002
4,000,000
1,280,000
49,200,000
920,000
534,000
18,251,000
2,006
2
2
1,800
2
4,000
72,453,000
companies to compete with foreignbased companies in domestic and
export markets.
Dated: July 29, 2005
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. 05–15493 Filed 8–4–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employment and Training
Administration
[TA–W–56,876]
American Wood Moulding, LLC, El
Paso, Texas; Notice of Negative
Determination Regarding Application
for Reconsideration
By application of May 18, 2005,
petitioners requested administrative
reconsideration of the Department’s
negative determination regarding
eligibility to apply for Trade Adjustment
Assistance (TAA), applicable to workers
and former workers of the subject firm.
The denial notice was signed on April
13, 2005, and published in the Federal
Register on May 16, 2005 (70 FR 25859).
Pursuant to 29 CFR 90.18(c)
reconsideration may be granted under
the following circumstances:
(1) If it appears on the basis of facts
not previously considered that the
determination complained of was
erroneous;
(2) If it appears that the determination
complained of was based on a mistake
in the determination of facts not
previously considered; or
(3) If in the opinion of the Certifying
Officer, a mis-interpretation of facts or
of the law justified reconsideration of
the decision.
E:\FR\FM\05AUN1.SGM
05AUN1
]]>Agencies
[Federal Register Volume 70, Number 150 (Friday, August 5, 2005)]
[Notices]
[Pages 45432-45435]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-15493]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-259R]
Controlled Substances: Proposed Revised Aggregate Production
Quotas for 2005
AGENCY: Drug Enforcement Administration (DEA), Justice.
ACTION: Notice of proposed revised 2005 aggregate production quotas.
-----------------------------------------------------------------------
SUMMARY: This notice proposes revised 2005 aggregate production quotas
for controlled substances in Schedules I and II of the Controlled
Substances Act (CSA).
DATES: Written comments must be postmarked, and electronic comments
[[Page 45433]]
must be sent, on or before August 26, 2005.
ADDRESSES: To ensure proper handling of comments, please reference
``Docket No. DEA-259R on all written and electronic correspondence.
Written comments being sent via regular mail should be sent to the
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration, Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL. Written comments sent via express
mail should be sent to DEA Headquarters, Attention: DEA Federal
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria,
VA 22301. Comments may be directly sent to DEA electronically by
sending an electronic message to dea.diversion.policy@usdoj.gov.
Comments may also be sent electronically through https://
www.regulations.gov using the electronic comment form provided on that
site. An electronic copy of this document is also available at the
https://www.regulations.gov Web site. DEA will accept attachments to
electronic comments in Microsoft Word, WordPerfect, Adobe PDF, or Excel
file formats only. DEA will not accept any file format other than those
specifically listed here.
FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, Ph.D., Chief,
Drug and Chemical Evaluation Section, Drug Enforcement Administration,
Washington, DC 20537, Telephone: (202) 307-7183.
SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826)
requires that the Attorney General establish aggregate production
quotas for each basic class of controlled substance listed in Schedules
I and II. This responsibility has been delegated to the Administrator
of the DEA by Section 0.100 of Title 28 of the Code of Federal
Regulations. The Administrator, in turn, has redelegated this function
to the Deputy Administrator, pursuant to Section 0.104 of Title 28 of
the Code of Federal Regulations.
On January 3, 2005, DEA published a notice of established initial
2005 aggregate production quotas for certain controlled substances in
Schedules I and II (70 FR 120). This notice stipulated that the DEA
would adjust the quotas in early 2005 as provided for in Part 1303 of
Title 21 of the Code of Federal Regulations.
The proposed revised 2005 aggregate production quotas represent
those quantities of controlled substances in Schedules I and II that
may be produced in the United States in 2005 to provide adequate
supplies of each substance for: the estimated medical, scientific,
research and industrial needs of the United States; lawful export
requirements; and the establishment and maintenance of reserve stocks.
These quotas do not include imports of controlled substances for use in
industrial processes.
The proposed revisions are based on a review of 2004 year-end
inventories, 2004 disposition data submitted by quota applicants,
estimates of the medical needs of the United States, product
development, and other information available to the DEA.
Therefore, under the authority vested in the Attorney General by
Section 306 of the CSA of 1970 (21 U.S.C. 826), delegated to the
Administrator of the DEA by Section 0.100 of Title 28 of the Code of
Federal Regulations, and redelegated to the Deputy Administrator
pursuant to Section 0.104 of Title 28 of the Code of Federal
Regulations, the Deputy Administrator hereby proposes the following
revised 2005 aggregate production quotas for the following controlled
substances, expressed in grams of anhydrous acid or base:
----------------------------------------------------------------------------------------------------------------
Previously
established initial Proposed revised 2005
Basic class--schedule I 2005 quotas quotas (grams)
(grams)
----------------------------------------------------------------------------------------------------------------
2,5-Dimethoxyamphetamine.......................................... 2,801,000 2,801,000
2,5-Dimethoxy-4-ethylamphetamine (DOET)........................... 2 2
2,5-Dimethoxy-4-(n)-propylthiophenethylamine...................... 10 10
3-Methylfentanyl.................................................. 2 2
3-Methylthiofentanyl.............................................. 2 2
3,4-Methylenedioxyamphetamine (MDA)............................... 15 15
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)...................... 5 5
3,4-Methylenedioxymethamphetamine(MDMA)........................... 15 17
3,4,5-Trimethoxyamphetamine....................................... 2 2
4-Bromo-2,5-dimethoxyamphetamine (DOB)............................ 2 2
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)........................ 2 2
4-Methoxyamphetamine.............................................. 2 5
4-Methylaminorex.................................................. 2 2
4-Methyl-2,5-dimethoxyamphetamine (DOM)........................... 2 2
5-Methoxy-3,4-methylenedioxyamphetamine........................... 2 2
5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT).................. 10 10
Acetyl-alpha-methylfentanyl....................................... 2 2
Acetyldihydrocodeine.............................................. 2 2
Acetylmethadol.................................................... 2 2
Allylprodine...................................................... 2 2
Alphacetylmethadol................................................ 2 2
Alpha-ethyltryptamine............................................. 2 2
Alphameprodine.................................................... 2 2
Alphamethadol..................................................... 3 3
Alpha-methyltryptamine (AMT)...................................... 10 10
Alpha-methylfentanyl.............................................. 2 2
Alpha-methylthiofentanyl.......................................... 2 2
Aminorex.......................................................... 2 2
Benzylmorphine.................................................... 2 2
Betacetylmethadol................................................. 2 2
Beta-hydroxy-3-methylfentanyl..................................... 2 2
Beta-hydroxyfentanyl.............................................. 2 2
Betameprodine..................................................... 2 2
Betamethadol...................................................... 2 2
[[Page 45434]]
Betaprodine....................................................... 2 2
Bufotenine........................................................ 2 2
Cathinone......................................................... 2 2
Codeine-N-oxide................................................... 252 252
Diethyltryptamine................................................. 2 2
Difenoxin......................................................... 5,000 5,000
Dihydromorphine................................................... 1,551,000 1,826,000
Dimethyltryptamine................................................ 3 3
Gamma-hydroxybutyric acid......................................... 8,000,000 8,000,000
Heroin............................................................ 2 2
Hydromorphinol.................................................... 2 2
Hydroxypethidine.................................................. 2 2
Lysergic acid diethylamide (LSD).................................. 61 61
Marihuana......................................................... 913,020 4,500,000
Mescaline......................................................... 2 2
Methaqualone...................................................... 5 5
Methcathinone..................................................... 4 4
Methyldihydromorphine............................................. 2 2
Morphine-N-oxide.................................................. 252 252
N,N-Dimethylamphetamine........................................... 2 2
N-Ethylamphetamine................................................ 2 2
N-Hydroxy-3,4-methylenedioxyamphetamine........................... 2 2
Noracymethadol.................................................... 2 2
Norlevorphanol.................................................... 52 52
Normethadone...................................................... 2 2
Normorphine....................................................... 12 12
Para-fluorofentanyl............................................... 2 2
Phenomorphan...................................................... 2 2
Pholcodine........................................................ 2 2
Propiram.......................................................... 50,000 50,000
Psilocybin........................................................ 2 2
Psilocyn.......................................................... 7 7
Tetrahydrocannabinols............................................. 312,500 312,500
Thiofentanyl...................................................... 2 2
Trimeperidine..................................................... 2 2
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
Previously
established initial Proposed revised
Basic class--schedule II 2005 quotas 2005 quotas
(grams) (grams)
----------------------------------------------------------------------------------------------------------------
1-Phenylcyclohexylamine............................................... 2 2
Alfentanil............................................................ 2,500 2,500
Alphaprodine.......................................................... 2 2
Amobarbital........................................................... 2 2
Amphetamine........................................................... 12,700,000 14,500,000
Cocaine............................................................... 228,000 228,000
Codeine (for sale).................................................... 39,605,000 39,605,000
Codeine (for conversion).............................................. 55,000,000 55,000,000
Dextropropoxyphene.................................................... 167,365,000 167,365,000
Dihydrocodeine........................................................ 748,000 750,000
Diphenoxylate......................................................... 571,000 828,000
Ecgonine.............................................................. 53,000 73,000
Ethylmorphine......................................................... 2 2
Fentanyl.............................................................. 1,428,000 1,428,000
Glutethimide.......................................................... 2 2
Hydrocodone (for sale)................................................ 37,604,000 37,604,000
Hydrocodone (for conversion).......................................... 1,500,000 1,500,000
Hydromorphone......................................................... 2,751,000 3,300,000
Isomethadone.......................................................... 2 2
Levo-alphacetylmethadol (LAAM)........................................ 2 2
Levomethorphan........................................................ 2 2
Levorphanol........................................................... 5,000 5,000
Meperidine............................................................ 9,753,000 9,753,000
Metazocine............................................................ 1 1
Methadone (for sale).................................................. 13,900,000 15,490,000
Methadone Intermediate................................................ 18,000,000 19,208,000
Methamphetamine....................................................... 2,932,000 2,340,000
-----------------------------------------------------------------------
[680,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 1,615,000 grams
for methamphetamine mostly for conversion to a Schedule III product; and 45,000 grams for methamphetamine (for
sale)]
----------------------------------------------------------------------------------------------------------------
Methylphenidate....................................................... 30,817,000 35,000,000 g
[[Page 45435]]
Morphine (for sale)................................................... 35,000,000 35,000,000
Morphine (for conversion)............................................. 110,774,000 110,774,000
Nabilone.............................................................. 2 2
Noroxymorphone (for sale)............................................. 1,002 1,002
Noroxymorphone (for conversion)....................................... 4,000,000 4,000,000
Opium................................................................. 1,180,000 1,280,000
Oxycodone (for sale).................................................. 49,200,000 49,200,000
Oxycodone (for conversion)............................................ 920,000 920,000
Oxymorphone........................................................... 534,000 534,000
Pentobarbital......................................................... 18,251,000 18,251,000
Phencyclidine......................................................... 2,006 2,006
Phenmetrazine......................................................... 2 2
Racemethorphan........................................................ 2 2
Remifentanil.......................................................... 0 1,800
Secobarbital.......................................................... 2 2
Sufentanil............................................................ 4,000 4,000
Thebaine.............................................................. 72,453,000 72,453,000
----------------------------------------------------------------------------------------------------------------
The Deputy Administrator further proposes that aggregate production
quotas for all other Schedules I and II controlled substances included
in Sections 1308.11 and 1308.12 of Title 21 of the Code of Federal
Regulations remain at zero.
All interested persons are invited to submit their comments in
writing or electronically regarding this proposal following the
procedures in the ``Addresses'' section of this document. A person may
object to or comment on the proposal relating to any of the above-
mentioned substances without filing comments or objections regarding
the others. If a person believes that one or more of these issues
warrant a hearing, the individual should so state and summarize the
reasons for this belief.
In the event that comments or objections to this proposal raise one
or more issues which the Deputy Administrator finds warrant a hearing,
the Deputy Administrator shall order a public hearing by notice in the
Federal Register, summarizing the issues to be heard and setting the
time for the hearing as per 21 CFR 1303.13(c).
The Office of Management and Budget has determined that notices of
aggregate production quotas are not subject to centralized review under
Executive Order 12866.
This action does not preempt or modify any provision of state law;
nor does it impose enforcement responsibilities on any state; nor does
it diminish the power of any state to enforce its own laws.
Accordingly, this action does not have federalism implications
warranting the application of Executive Order 13132.
The Deputy Administrator hereby certifies that this action will not
have a significant impact upon small entities whose interests must be
considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et seq.
The establishment of aggregate production quotas for Schedules I and II
controlled substances is mandated by law and by international treaty
obligations. The quotas are necessary to provide for the estimated
medical, scientific, research and industrial needs of the United
States, for export requirements and the establishment and maintenance
of reserve stocks. While aggregate production quotas are of primary
importance to large manufacturers, their impact upon small entities is
neither negative nor beneficial. Accordingly, the Deputy Administrator
has determined that this action does not require a regulatory
flexibility analysis.
This action meets the applicable standards set forth in Sections
3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform.
This action will not result in the expenditure by State, local, and
tribal governments, in the aggregate, or by the private sector, of
$115,000,000 or more in any one year, and will not significantly or
uniquely affect small governments. Therefore, no actions were deemed
necessary under the provisions of the Unfunded Mandates Reform Act of
1995.
This action is not a major rule as defined by Section 804 of the
Small Business Regulatory Enforcement Fairness Act of 1996. This action
will not result in an annual effect on the economy of $100,000,000 or
more; a major increase in costs or prices; or significant adverse
effects on competition, employment, investment, productivity,
innovation, or on the ability of United States-based companies to
compete with foreign-based companies in domestic and export markets.
Dated: July 29, 2005
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. 05-15493 Filed 8-4-05; 8:45 am]
BILLING CODE 4410-09-P
